Laboratorio de Terapia Celular, Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Av. Dr. José Eleuterio González 235, Monterrey 64460, Nuevo León, Mexico.
Departamento de Ciencias Básicas, Vicerrectoría de Ciencias de la Salud, Universidad de Monterrey, Ignacio Morones Prieto 4500. Jesus M. Garza, San Pedro Garza García 66238, Nuevo León, Mexico.
Int J Mol Sci. 2023 May 3;24(9):8163. doi: 10.3390/ijms24098163.
Cancer stem cells (CSCs) are a small subpopulation of cells within tumors with properties, such as self-renewal, differentiation, and tumorigenicity. CSCs have been proposed as a plausible therapeutic target as they are responsible for tumor recurrence, metastasis, and conventional therapy resistance. Selectively targeting CSCs is a promising strategy to eliminate the propagation of tumor cells and impair overall tumor development. Recent research shows that several immune cells play a crucial role in regulating tumor cell proliferation by regulating different CSC maintenance or proliferation pathways. There have been great advances in cellular immunotherapy using T cells, natural killer (NK) cells, macrophages, or stem cells for the selective targeting of tumor cells or CSCs in colorectal cancer (CRC). This review summarizes the CRC molecular profiles that may benefit from said therapy and the main vehicles used in cell therapy against CSCs. We also discuss the challenges, limitations, and advantages of combining conventional and/or current targeted treatments in the late stages of CRC.
癌症干细胞（CSC）是肿瘤内具有自我更新、分化和致瘤性等特性的一小部分细胞。CSC 被认为是一种合理的治疗靶点，因为它们是肿瘤复发、转移和常规治疗耐药的原因。选择性靶向 CSC 是消除肿瘤细胞增殖和损害整体肿瘤发展的有前途的策略。最近的研究表明，几种免疫细胞通过调节不同的 CSC 维持或增殖途径在调节肿瘤细胞增殖方面发挥着重要作用。使用 T 细胞、自然杀伤（NK）细胞、巨噬细胞或干细胞进行细胞免疫疗法在结直肠癌（CRC）中选择性靶向肿瘤细胞或 CSC 方面取得了巨大进展。本综述总结了可能受益于该疗法的 CRC 分子谱，以及针对 CSC 细胞治疗中使用的主要载体。我们还讨论了将传统和/或当前靶向治疗联合应用于 CRC 晚期的挑战、局限性和优势。
